Otrivin spray with menthol and eucalyptus quickly relieves nasal congestion and leaves a cooling sensation. For a runny nose and sinusitis.
International Name: Xylometazoline
Composition
Each 1 mL of solution contains:
Active ingredient: Xylometazoline hydrochloride — 1 mg.
Excipients: Sodium dihydrogen phosphate dihydrate, disodium phosphate dodecahydrate, sodium chloride, benzalkonium chloride, sorbitol, disodium edetate, levomenthol (menthol), cineole (eucalyptol), Cremophor RH 40, purified water.
Pharmacotherapeutic Group
Decongestants and other nasal preparations for topical use. Sympathomimetics.
Indications
Rhinitis of various origins.
To facilitate the drainage of accumulated secretions from the nasal cavity and paranasal sinuses during sinus inflammation.
As adjunctive therapy for otitis media, to reduce swelling of the nasopharyngeal mucosa.
To facilitate rhinoscopy.
Method of Administration and Dosage
Adults and children over 12 years of age: One spray into each nostril 3 times daily. Repeat if necessary. Use more than 3 times daily is not recommended.
The last spray is recommended before bedtime.
Do not use Otrivin for more than 1 week, as prolonged use may cause rhinitis medicamentosa.
Directions for Use
Before use, clear the nasal cavity thoroughly. Remove the protective cap. Before the first use, press the applicator several times until a spray stream appears. The spray is then ready for subsequent use.
If spraying remains incomplete after repeated pressing of the applicator, for example, after a temporary interruption in use, press the applicator 4 more times.
Insert the nozzle into the nostril and press the applicator once quickly while gently inhaling through the nose. This helps distribute the spray optimally throughout the nasal cavity. Replace the protective cap after use.
Precautions
Otrivin should be used with caution in:
Patients with arterial hypertension or cardiovascular diseases;
Patients with hyperthyroidism, diabetes mellitus, or pheochromocytoma;
Patients with prostatic hypertrophy;
Patients who are receiving or have received monoamine oxidase inhibitors within the past 14 days.
